Veradermics Incorporated
Veradermics Incorporated (MANE): 8 pipeline candidates · 3 upcoming catalysts · ~54 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
54.1 months
D/E 0.02 · 0% dilution
Lead: Approved
8 candidates
3 upcoming, next in ~75d
26 buys · 0 sells (180d)
A transparent, data-derived signal for Veradermics Incorporatedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.8B
Cash
$168.4M
Quarterly Burn
$21.2M
Runway
54.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| annovera | Approved |
| annovera | Approved |
| bijuva | Approved |
| imvexxy | Approved |
| vdphl01 | Phase 3 |
| vdphl01 bid | Phase 3 |
| vdphl01 qd | Phase 3 |
| vehicle | Phase 2 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$1.37B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 4,168,970 | $263.3M |
| citadel advisors llc | 1,825,672 | $115.3M |
| fmr llc | 1,792,909 | $113.2M |
| viking global investors lp | 1,690,555 | $106.8M |
| vanguard capital management llc | 1,399,290 | $88.4M |
| adage capital partners gp, l.l.c. | 1,100,000 | $69.5M |
| woodline partners lp | 1,001,292 | $63.2M |
| infinitum asset management, llc | 731,149 | $46.2M |
| marshall wace, llp | 654,601 | $41.3M |
| vivo capital, llc | 600,000 | $37.9M |
Showing top 10 of 77 institutional holders of Veradermics Incorporated. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Veradermics Incorporated's pipeline?
Veradermics Incorporated (MANE) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Veradermics Incorporated's lead drug candidate?
Veradermics Incorporated's most advanced tracked candidate is annovera (Approved).
What is Veradermics Incorporated's next catalyst?
Veradermics Incorporated's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff" — expected September 1, 2026.
What is Veradermics Incorporated's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Veradermics Incorporated has approximately 54.1 months of cash runway.
What is Veradermics Incorporated's market capitalization?
Veradermics Incorporated's market capitalization is approximately $3.8B.
Get the full picture on Veradermics Incorporated
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.